GO:0031770 growth hormone-releasing hormone receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031770 (growth hormone-releasing hormone receptor binding) is a molecular function describing the binding of a ligand to the growth hormone-releasing hormone receptor (GHRHR).
• The principal ligand is growth hormone-releasing hormone (GHRH), a hypothalamic peptide that activates GHRHR to stimulate growth hormone synthesis and release.
• GHRHR is a class B G protein-coupled receptor; its activation involves ligand binding to the extracellular domain and subsequent conformational changes that engage Gs signaling.
• GHRH and GHRHR are expressed in multiple cancers, where they can act as autocrine/paracrine growth factors, making this binding event a therapeutic target.
• Mutations in GHRHR cause isolated growth hormone deficiency, and splice variants of the receptor are found in pediatric hematological and oncological disorders.
• Studying this binding function requires tools such as radioligand binding, cAMP assays, CRISPR knockout/knock-in models, and structural biology.
Description
GO:0031770, growth hormone-releasing hormone receptor binding, is a molecular function term that describes the physical interaction between a ligand and the growth hormone-releasing hormone receptor (GHRHR). This binding event is the first step in a signaling cascade that controls growth hormone (GH) secretion from the anterior pituitary and also influences cell proliferation in peripheral tissues. The primary endogenous ligand is growth hormone-releasing hormone (GHRH), a 44-amino-acid peptide produced in the hypothalamus, although other ligands and splice variants may also engage the receptor. Understanding this binding function is essential for researchers studying neuroendocrinology, growth disorders, and cancer biology. The GHRHR is a class B G protein-coupled receptor (GPCR) that couples primarily to Gs, leading to adenylyl cyclase activation and cAMP accumulation. Structural studies have revealed how GHRH binds to the extracellular domain of GHRHR and induces conformational changes that enable G protein coupling. This binding event is not limited to the pituitary; GHRH and GHRHR are expressed in various tumors, where they can stimulate proliferation and survival. Therefore, GO:0031770 is a focal point for both basic signaling research and translational oncology. Researchers investigating this term often need to determine whether a candidate gene or mutation affects GHRH-GHRHR binding and downstream signaling. This article provides a comprehensive overview of the definition, mechanism, key genes, disease associations, and experimental methods relevant to GO:0031770, with an emphasis on CRISPR-based approaches for functional validation.
growth hormone-releasing hormone receptor binding At A Glance
| GO ID | GO:0031770 |
|---|---|
| GO term | growth hormone-releasing hormone receptor binding |
| Ontology | molecular_function |
| Synonym | growth hormone-releasing hormone receptor ligand |
| Major function | Binding of a ligand to the growth hormone-releasing hormone receptor (GHRHR), initiating receptor activation and downstream signaling. |
| Primary ligand | Growth hormone-releasing hormone (GHRH). |
| Receptor | GHRHR, a class B G protein-coupled receptor. |
| Downstream signaling | Gs-mediated activation of adenylyl cyclase, cAMP production, and PKA signaling. |
| Disease relevance | Isolated growth hormone deficiency, cancer (e.g., endometrial, hematological). |
What Is GO:0031770?
According to the Gene Ontology, GO:0031770 is defined as "Binding to a growth hormone-releasing hormone receptor." In other words, it is the molecular function of a ligand (such as GHRH) physically interacting with the growth hormone-releasing hormone receptor (GHRHR). This term encompasses the initial recognition and binding step, which is a prerequisite for receptor activation and downstream signaling.
Why Is growth hormone-releasing hormone receptor binding Important in Cell Biology?
GO:0031770 is important because the binding of GHRH to its receptor is a critical control point for growth hormone secretion and for the proliferation of certain cancers. Dysregulation of this binding event can lead to growth disorders such as isolated growth hormone deficiency, and it is increasingly recognized as a driver in oncology, where autocrine/paracrine GHRH-GHRHR loops promote tumor growth. Understanding the molecular details of this binding function can inform the development of antagonists and targeted therapies.
• Regulates growth hormone synthesis and release from the pituitary.
• Mutations in GHRHR cause isolated growth hormone deficiency, a rare growth disorder.
• GHRH and GHRHR are expressed in various cancers, including endometrial and hematological malignancies.
• The binding event is a target for therapeutic antagonists in cancer and endocrine disorders.
• Structural insights into GHRH-GHRHR binding aid rational drug design.
• Splice variants of GHRHR can alter binding and signaling, contributing to disease heterogeneity.
• Understanding this function helps interpret genetic variants of uncertain significance in GHRHR.
• It serves as a model for class B GPCR ligand recognition and activation.
Molecular Mechanism of growth hormone-releasing hormone receptor binding
Ligand Recognition and Binding
In simple terms: The GHRH peptide docks onto the receptor like a key in a lock.
The binding of GHRH to GHRHR is initiated by the interaction of the GHRH peptide with the extracellular domain of the receptor. Structural studies have shown that the C-terminal portion of GHRH binds to the N-terminal extracellular domain of GHRHR, while the N-terminal region of GHRH interacts with the transmembrane core to stabilize the active conformation. This two-step binding mechanism is characteristic of class B GPCRs and ensures high specificity and affinity.
Receptor Conformational Change and G Protein Coupling
In simple terms: Once the ligand binds, the receptor changes shape and activates a G protein inside the cell.
Ligand binding induces conformational changes in the GHRHR, particularly in the transmembrane helices, which create a binding pocket for the Gs protein. This leads to the exchange of GDP for GTP on the Gs alpha subunit, dissociation of the G protein, and activation of adenylyl cyclase. The resulting increase in cAMP activates protein kinase A (PKA) and other downstream effectors, culminating in growth hormone gene transcription and secretion.
Regulation by Splice Variants and Accessory Proteins
In simple terms: Different versions of the receptor can change how well the hormone binds.
Alternative splicing of GHRHR can produce variants that differ in their extracellular or intracellular domains, potentially altering ligand binding affinity or signaling efficacy. These splice variants have been detected in pediatric hematological and oncological disorders, suggesting they may modulate GHRH responsiveness in disease contexts. Additionally, accessory proteins such as RAMPs (receptor activity-modifying proteins) may influence GHRHR trafficking and ligand binding, although direct evidence for GHRHR is still emerging.
Termination and Desensitization
In simple terms: The signal is turned off after a while to prevent overstimulation.
Following activation, GHRHR is phosphorylated by G protein-coupled receptor kinases (GRKs) and binds arrestins, leading to receptor internalization and desensitization. This negative feedback is crucial for preventing prolonged growth hormone release and for maintaining pituitary homeostasis. Dysregulation of desensitization can contribute to endocrine disorders and may be exploited by cancer cells to sustain proliferative signaling.
Key Genes Involved in GO:0031770 growth hormone-releasing hormone receptor binding
The following genes and proteins are directly involved in or regulate growth hormone-releasing hormone receptor binding (GO:0031770).
| Gene | Major Role | Research Relevance |
|---|---|---|
| GHRH | Encodes the primary ligand that binds GHRHR. | Target for knockout/knock-in to study ligand-receptor interaction. |
| GHRHR | Encodes the receptor that binds GHRH. | Central to binding assays and mutational analysis. |
| GH1 | Encodes growth hormone, the downstream effector. | Readout for GHRHR activation in pituitary cells. |
| GNAS | Encodes Gs alpha subunit, mediates GHRHR signaling. | Knockout alters cAMP response to GHRH. |
| ADCYAP1 | Encodes PACAP, a related peptide with partial homology to GHRH. | Can be used to study ligand specificity. |
| POU1F1 | Pituitary-specific transcription factor regulating GHRHR expression. | Knockout affects GHRHR levels. |
| GHRH-R splice variants | Alternatively spliced forms of GHRHR with altered binding. | Investigated in cancer and pediatric disorders. |
| ARRB1 | Beta-arrestin 1, involved in GHRHR desensitization. | Knockout prolongs GHRH signaling. |
| GRK2 | G protein-coupled receptor kinase 2, phosphorylates GHRHR. | Modulates receptor internalization. |
| CREB1 | Transcription factor activated by cAMP/PKA pathway. | Reporter assays for GHRHR activation. |
| SSTR2 | Somatostatin receptor 2, opposes GHRH action. | Co-expression studies with GHRHR. |
| IGF1 | Mediates growth-promoting effects of GH. | Downstream biomarker in GHRH/GHRHR studies. |
| PITX1 | Transcription factor involved in pituitary development. | Affects GHRHR expression. |
| PROP1 | Pituitary transcription factor; mutations cause combined pituitary hormone deficiency. | Model for GHRHR dysregulation. |
| GHRH-R antagonists | Synthetic peptides that block GHRH binding. | Used in cancer research to inhibit proliferation. |
How Is growth hormone-releasing hormone receptor binding Regulated?
The binding of GHRH to GHRHR is regulated at multiple levels. Expression of GHRHR on pituitary somatotrophs is controlled by transcription factors such as POU1F1 and PROP1. Ligand availability is regulated by hypothalamic secretion of GHRH and somatostatin, which inhibits GHRH release. At the receptor level, desensitization and internalization are mediated by GRKs and arrestins. In cancer cells, autocrine/paracrine GHRH production can sustain receptor activation, and splice variants may escape normal regulatory control.
growth hormone-releasing hormone receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GHRHR | Isolated growth hormone deficiency | Knock-in of patient mutations in cell lines; KO in pituitary cells. |
| GHRH | Cancer proliferation | Overexpression in cancer cell lines; KO to reduce autocrine signaling. |
| GHRHR splice variants | Pediatric hematological/oncological disorders | Knock-in of specific splice variants; RNA-seq to study isoform effects. |
| GNAS | Endocrine and proliferative signaling | Point mutation to disrupt Gs coupling; cAMP assays. |
| ARRB1 | Receptor desensitization in disease | Knockout to study prolonged signaling. |
Isolated Growth Hormone Deficiency (IGHD)
Mutations in GHRHR that impair GHRH binding or receptor activation cause isolated growth hormone deficiency, characterized by short stature and low GH levels. These mutations often affect the extracellular domain, directly disrupting the binding function described by GO:0031770. Functional studies of these mutants are essential for diagnosis and genetic counseling.
Cancer
GHRH and GHRHR are expressed in various cancers, including endometrial carcinoma and pediatric hematological malignancies. In these contexts, GHRH binding to GHRHR can stimulate proliferation, migration, and survival through autocrine/paracrine loops. Splice variants of GHRHR may alter binding specificity and contribute to tumor heterogeneity. Targeting this binding event with antagonists is an active area of therapeutic research.
Pediatric Hematological and Oncological Disorders
A pilot study in Hungarian pediatric patients found expression of GHRH and GHRHR splice variants in hematological and oncological disorders, suggesting a role for this binding function in pediatric malignancies. The presence of these variants may influence disease progression and response to therapy.
From growth hormone-releasing hormone receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a GHRHR mutation affect ligand binding? | Point mutation knock-in in HEK293 or pituitary cell lines. |
| What is the effect of GHRH overexpression in cancer? | Overexpression cell model (e.g., endometrial cancer cells). |
| Which genes are essential for GHRH-GHRHR signaling? | CRISPR knockout library screening in relevant cell lines. |
| How does a splice variant alter receptor function? | Knock-in of specific splice variant using CRISPR. |
| Can we visualize GHRHR trafficking? | Tagged knock-in (e.g., GFP) for live-cell imaging. |
| What is the transcriptional response to GHRH? | RNA-seq after GHRH stimulation in KO vs wild-type cells. |
How to Study the growth hormone-releasing hormone receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Direct ligand-receptor interaction | Determining affinity of GHRH analogs. |
| cAMP assay | Gs-mediated signaling | Screening for agonists/antagonists. |
| Cryo-EM | 3D structure of receptor-ligand complex | Understanding binding mechanism. |
| CRISPR knockout | Loss-of-function effects | Validating gene necessity in signaling. |
| CRISPR knock-in | Effect of specific mutations | Modeling patient variants. |
| RNA-seq | Transcriptional changes | Identifying downstream targets. |
| Western blot | Protein expression and phosphorylation | Measuring GHRHR and downstream effectors. |
| Immunofluorescence | Cellular localization | Studying receptor trafficking. |
Radioligand Binding Assays
Radioligand binding assays using iodinated GHRH are the gold standard for measuring direct binding to GHRHR. These assays can determine affinity (Kd) and receptor density (Bmax) and are used to evaluate mutants or antagonists.
cAMP and Reporter Assays
Since GHRHR couples to Gs, cAMP accumulation is a robust readout of receptor activation. Luciferase reporters driven by cAMP response elements (CRE) are commonly used to measure GHRH-induced signaling in high-throughput formats.
Structural Biology (Cryo-EM and X-ray Crystallography)
Cryo-electron microscopy has been used to solve the structure of GHRHR in complex with GHRH and Gs, revealing the molecular details of ligand binding and receptor activation. These structures guide mutagenesis and drug design.
CRISPR-Based Functional Genomics
CRISPR knockout and knock-in models allow researchers to test the causal role of GHRHR and its partners in binding and signaling. Pooled library screening can identify modifiers of GHRH responsiveness.
How CRISPR Can Be Used to Study GO:0031770 growth hormone-releasing hormone receptor binding
Knockout
CRISPR knockout of GHRHR or GHRH can abolish ligand binding and downstream signaling, providing a clean background to study the function of GO:0031770. Knockout models are useful for validating specificity of binding assays and for identifying compensatory pathways.
Point Mutation
Introducing point mutations in GHRHR that correspond to patient variants (e.g., in the extracellular domain) allows precise testing of their impact on GHRH binding and receptor activation. This approach is essential for classifying variants of uncertain significance.
Knock-in
Knock-in of tagged GHRHR (e.g., HA or GFP) enables visualization and biochemical isolation of the receptor without altering its binding properties. Knock-in of splice variants can reveal their specific binding characteristics.
Overexpression
Overexpression of GHRH or GHRHR in cell lines can create autocrine/paracrine loops that mimic cancer conditions, allowing researchers to study the role of this binding function in proliferation and survival. Overexpression models are also used for high-throughput drug screening.
How EDITGENE Supports growth hormone-releasing hormone receptor binding Research
Researchers studying growth hormone-releasing hormone receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand binding, receptor activation, or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for growth hormone-releasing hormone receptor binding research.
Frequently Asked Questions About growth hormone-releasing hormone receptor binding
What is GO:0031770?
GO:0031770 is the Gene Ontology molecular function term for growth hormone-releasing hormone receptor binding, defined as binding to a growth hormone-releasing hormone receptor.
What genes are involved in growth hormone-releasing hormone receptor binding?
The primary genes are GHRH (ligand) and GHRHR (receptor), along with downstream effectors like GNAS and GH1.
What is the function of growth hormone-releasing hormone receptor binding?
It initiates a signaling cascade that stimulates growth hormone synthesis and release, and can also promote cell proliferation in peripheral tissues.
Which diseases are associated with GHRHR mutations?
Mutations in GHRHR can cause isolated growth hormone deficiency, and GHRHR is also implicated in certain cancers.
How can I study growth hormone-releasing hormone receptor binding?
Common methods include radioligand binding assays, cAMP assays, structural biology, and CRISPR-based knockout or knock-in models.
What are the splice variants of GHRHR?
Alternative splicing of GHRHR produces variants that may differ in ligand binding or signaling, and these have been found in pediatric hematological and oncological disorders.
Is GHRH-GHRHR signaling involved in cancer?
Yes, autocrine/paracrine GHRH-GHRHR loops can stimulate proliferation and survival in various cancers, making this binding event a therapeutic target.
What is the structure of the GHRH-GHRHR complex?
Cryo-EM studies have revealed that GHRH binds to the extracellular domain of GHRHR and induces conformational changes for Gs coupling.
Can CRISPR be used to study GHRHR function?
Yes, CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect the role of GHRHR in binding and signaling.
What services does EDITGENE offer for GHRHR research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services tailored to GHRHR and related genes.
Conclusion
GO:0031770, growth hormone-releasing hormone receptor binding, is a fundamental molecular function that controls growth hormone secretion and has broad implications in endocrine disorders and cancer. Understanding its mechanism, key genes, and disease relevance is essential for both basic and translational research. With advanced CRISPR tools and services from EDITGENE, researchers can precisely dissect this binding event and accelerate the development of targeted therapies.
References
- 1. Halmos G et al.. 2023. Signaling mechanism of growth hormone-releasing hormone receptor.. Vitam Horm 123:1-26 PMID: 37717982
- 2. Halmos G et al.. 2025. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling.. Rev Endocr Metab Disord 26(3):343-352 PMID: 39934495
- 3. Gesmundo I et al.. 2025. Growth hormone-releasing hormone and cancer.. Rev Endocr Metab Disord 26(3):443-456 PMID: 39422787
- 4. Zhou F et al.. 2020. Structural basis for activation of the growth hormone-releasing hormone receptor.. Nat Commun 11(1):5205 PMID: 33060564
- 5. Juhász É et al.. 2024. Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in a Cohort of Hungarian Pediatric Patients with Hematological and Oncological Disorders: A Pilot Study.. Int J Mol Sci 25(16) PMID: 39201517
- 6. Szabo Z et al.. 2022. Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches.. Molecules 27(9) PMID: 35566020
- 7. Gaylinn BD. 2002. Growth hormone releasing hormone receptor.. Recept Channels 8(3-4):155-62 PMID: 12529933
- 8. Martari M et al.. 2009. Diseases associated with growth hormone-releasing hormone receptor (GHRHR) mutations.. Prog Mol Biol Transl Sci 88:57-84 PMID: 20374725
